Synonyms: PF-04383119 | PF04383119 | RN624
Compound class:
Antibody
Comment: Tanezumab is an investigational monoclonal antibody targeting nerve growth factor (NGF). NGF is a neurotrophin that regulates the development and survival of a select population of neurons through the binding and activation of the neurotrophic receptor tyrosine kinase 1 (TrkA receptor). Elevated levels of NGF have been associated with painful pathologies including diabetic neuropathy, fibromyalgia and osteoarthritis, and cancer apin. Inhibition of NGF signalling has been explored for anti-pain potential.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical sequences are claimed in patent US7449616. |
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
8941 | tanezumab |
Synonyms ![]() |
PF-04383119 | PF04383119 | RN624 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 230 |
Other databases | |
GtoPdb PubChem SID | 252166625 |
Search PubMed clinical trials | tanezumab |
Search PubMed titles | tanezumab |
Search PubMed titles/abstracts | tanezumab |
Wikipedia | Tanezumab |